NDTVCenter·
178% Intraday Surge: This US Biopharma Stock Skyrockets After Eye Disease Drug Clears Key Hurdle
Kodiak said the completion of five successful Phase 3 trials positions the company to submit the treatments for US Food and Drug Administration approval later this year.
Read at NDTV →
